Objectives: Patients frequently present to the emergency department (ED) with neck or back pain, which can be difficult to treat. We sought to compare ultrasound-guided trigger point injection (TPI) to standard medications for patients with neck or back pain.
Methods: We performed a single-center, open label, randomized controlled trial on ED patients with neck or back pain from myofascial pain syndrome comparing ultrasound-guided TPIs to those who received the combination of a nonsteroidal anti-inflammatory drug (NSAID) and a muscle relaxant (MR). The primary outcome of this study was the reduction in mean pain score at the time of ED disposition.
Results: In total, we analyzed 196 patients. At the time of ED disposition, patients in the TPI group had a mean reduction in their pain scores of 45.0 mm as compared to 49.9 mm in the NSAID plus MR group (difference: 4.9 [95% confidence interval (CI) -3.0 to 12.7], P = .22). At the first reassessment, patients in the TPI group had greater pain reduction by 10.7 mm (95% CI 3.1 to 18.4). The rate of rescue therapy use was higher in the NSAID plus MR group (difference: 17.5% [95% CI 4.4 to 36.2]).
Conclusions: We found no difference in pain reduction at the time of ED disposition between patients randomized to the ultrasound-guided TPI group as compared to those who received an NSAID plus a MR. However, patients in the TPI group had greater pain reduction at the time of first reassessment and lower rates of rescue therapy use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jum.16113 | DOI Listing |
Alzheimers Dement
December 2024
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Background: Population-based functional connectomes help explain heterogeneity in tau spread in Alzheimer's disease by demonstrating spread among connected neurons from canonical epicenters. However, if the hypothesis of cell-to-cell transmission of tau is correct, individual structural connectomes seeded from individual-specific epicenters of PET-tau pathology should improve prediction of regional tau patterns.
Method: 86 participants from the Penn Aging Brain Cohort and 158 participants from ADNI with multi-shell diffusion MRI and AV1451 Tau PET within 18 months of each other were included.
Alzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: Measures of tau burden have typically relied upon measures of magnitude, such as mean standardized uptake value ratio (SUVR), or extent, such as number of tau positive regions. However, heterogenous patterns of tau spread and accumulation present challenges to using these measures in isolation to quantify tau burden. Therefore, we hypothesized that a combined measure of tau magnitude and extent (Tau-MaX) would outperform either measure in isolation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Background: Population-based functional connectomes help explain heterogeneity in tau spread in Alzheimer's disease by demonstrating spread among connected neurons from canonical epicenters. However, if the hypothesis of cell-to-cell transmission of tau is correct, individual structural connectomes seeded from individual-specific epicenters of PET-tau pathology should improve prediction of regional tau patterns.
Method: 86 participants from the Penn Aging Brain Cohort and 158 participants from ADNI with multi-shell diffusion MRI and AV1451 Tau PET within 18 months of each other were included.
Cancers (Basel)
December 2024
Medical Oncology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Background: For patients with refractory metastatic colorectal cancer (mCRC), trifluridine/tipiracil (FTD-TPI) has been associated with a significant improvement in overall survival (OS). However, data are lacking regarding the activity of FTD-TPI in patients with -mutated mCRC.
Methods: This retrospective, multicenter, international cohort included patients with -mutated mCRC treated with FTD-TPI in a real-life setting in Spain and Italy.
BMC Cancer
January 2025
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kita-Ku, Okayama, 700-8558, Japan.
Objective: Trifluridine/tipiracil (FTD/TPI) is one of the options for late-line treatment of colorectal cancer (CRC). However, the specific patient populations that would particularly benefit from it remain unclear. This study attempted to identify predictive markers of chemotherapy efficacy with trifluridine/tipiracil (FTD/TPI), focusing on the RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) expression and neutrophil-lymphocyte ratio (NLR).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!